0329 GMT - Pro Medicus's bulls at Goldman Sachs lift their earnings forecasts for the next two full fiscal years following the Australian imaging-tech provider's latest contract wins. The GS analysts make no change to their forecast of 38% earnings growth in the current 2025 fiscal year, but lift expectations by 2% for fiscal 2026 and by 4% for fiscal 2027. They tell clients in a note that they don't anticipate any guidance to be provided with the company's first-half result announcement, but do expect positive commentary on the strength of its contract pipeline. GS lifts its target price by 8.9% to A$310.00 and keeps a buy rating on the stock. Shares are up 1.25% at A$287.48. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 04, 2025 22:29 ET (03:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.